Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Clinical trial NCT07680790 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07680790
- Sponsor
- Bristol-Myers Squibb
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-30
- Primary completion
- 2031-12-30
- Enrollment
- 850
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.